Abliva AB Interim Report January – September 2023
KL1333 Received FDA Fast Track Designation | The FALCON Study Reached an Important Milestone
Press releases
Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury
Abliva AB (‘Abliva’ or the ‘Company’) and US-based Owl Therapeutics today announced the signing of a licensing and collaboration agreement for Abliva’s NeuroSTAT® for the treatment of moderate to seve ...
Abliva Achieves Important Milestone in the Ongoing FALCON Study
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company has now included the t ...
Abliva to Participate in World Mitochondrial Disease Week 2023
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will participate in W ...
Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company’s lead candidate KL133 ...
Abliva AB Interim Report January – June 2023
The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354
Abliva presents at UMDF Mitochondrial Medicine 2023
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will present at UMDF’ ...
Abliva announces first patient dosed in the FALCON study
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the first patient has been dosed ...
Abliva presents scientific data at international conference on mitochondrial medicine
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will present scientif ...
Abliva AB Interim Report January – March 2023
Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 5, 2023, held its Annual General Meeting (“AGM”). A summary of the resolution follows.
Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023
The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee's proposal for the election of Board members was […] ...